How do you pay?

How to pay the least

Ask for the cash price

Lifyorli

We didn’t find one.

  1. Ask your pharmacy for Lifyorli’s cash price, and one or two other pharmacies too.
  2. Lifyorli’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameLifyorli
Authorized genericrelacorilant
Regular genericrelacorilant
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Lifyorli?
The original
–
–

Brand nameThe maker’s card

LIFYORLI Savings Card Program

Savings card from Corcept Therapeutics

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a month

The card takes up to $25,000 a year off your co-pay.

Sign up on lifyorlisavingscard.com 

Or call 1-855-439-6754.

In the maker’s words

“little as $0 per month for LIFYORLI…”

From the maker’s offer on lifyorlisavingscard.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Lifyorli itself, from the same company, sold without the brand name, and usually for less. For now Lifyorli is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Source: the FDA label for Lifyorli (Corcept Therapeutics Incorporated), March 26, 2026. Full label on DailyMed 

Good to know